From: Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic patients
Variable
Number of patients (n = 18)
Age (years)
Median (range)
41 (25–67)
Gender
Male
10 (55.5 %)
Female
8 (44.4 %)
Type of immunotherapy
TriMixIpi
11 (61.1 %)
Ipi
7 (38.8 %)
Response to immunotherapy
DB
5 (27.7 %)
NB
13 (72.2 %)